Education
About Us
Working with TipRanks
Follow Us
Bridgebio Pharma (BBIO)
:BBIO
Earnings Data
Report Date
Oct 30, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.82Last Year’s EPS
-0.86Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call was largely positive with the successful launch of Attruby driving significant revenue and the strong progress of the pipeline. While there were increased SG&A expenses due to the commercial rollout, the overall impact was minimal compared to the positive developments.Company Guidance -
Q3 2025
Successful Attruby Launch
Attruby generated $36.7 million in revenue in its first quarter, with 2,072 unique patients receiving a prescription and 756 unique healthcare providers writing at least one prescription. The product demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, including a 50% reduction in cardiovascular hospitalization.
Pipeline Progress
BridgeBio's pipeline includes three Phase 3 readouts expected in the next year, with trials in limb-girdle muscular dystrophy 2I, achondroplasia, and ADH1 on track. Additionally, the hypochondroplasia trial enrolled its first patient quickly, and positive POC data for encaleret in hypoparathyroidism was announced.
Financial Performance
Total revenues for Q1 2025 were $116.6 million, exceeding expectations. The company's NPV increased by 9% due to various factors, including better-than-anticipated revenue from Attruby and a successful convertible offering.
Strong Market Positioning
Attruby is positioned as the most cost-effective therapy in the ATTR-CM market, being 10% less expensive than tafamidis and 50% less expensive than vutrisiran. It also offers a free trial program for all patients and lifetime free drug for trial participants.
BBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 05, 2025 | $49.21 | $44.81 | -8.94% |
Apr 29, 2025 | $36.42 | $38.36 | +5.33% |
Feb 20, 2025 | $36.29 | $36.80 | +1.41% |
Nov 12, 2024 | $26.12 | $24.62 | -5.74% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bridgebio Pharma (BBIO) report earnings?
Bridgebio Pharma (BBIO) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).
What is Bridgebio Pharma (BBIO) earnings time?
Bridgebio Pharma (BBIO) earnings time is at Oct 30, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BBIO EPS forecast?
BBIO EPS forecast for the fiscal quarter 2025 (Q3) is -0.82.